Previous close | 20.57 |
Open | 20.56 |
Bid | 21.13 x 100 |
Ask | 21.19 x 100 |
Day's range | 20.42 - 21.18 |
52-week range | 20.42 - 79.65 |
Volume | |
Avg. volume | 671,512 |
Market cap | 1.137B |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
Prothena ( NASDAQ:PRTA ) Full Year 2023 Results Key Financial Results Revenue: US$91.4m (up 70% from FY 2022). Net...
Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.